MAYA BEPLAT: Open Payments
NPI 1043722655 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,070 in 61 payments from 25 companies in 2025. Trend: 2023 $1,551 · 2024 $1,482 · 2025 $2,070
Food & beverage: $1,878Education: $192
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $446 |
| Daiichi Sankyo Inc. | 10 | $234 |
| Gilead Sciences, Inc. | 3 | $195 |
| ABBVIE INC. | 3 | $172 |
| Novartis Pharmaceuticals Corporation | 7 | $167 |
| Lilly USA, LLC | 2 | $116 |
| JAZZ PHARMACEUTICALS INC. | 2 | $101 |
| Merck Sharp & Dohme LLC | 4 | $93 |
| TerSera Therapeutics LLC | 3 | $60 |
| Stemline Therapeutics Inc. | 2 | $56 |
Products named: RYBREVANT, ERLEADA, Trodelvy, VENCLEXTA, Enhertu, DATROWAY, ZEPZELCA, KISQALI.
Industry payments across DC — which companies pay providers there.
